Navigation Links
New discovery could dramatically reduce leishmaniasis treatment doses and side effects
Date:11/5/2013

The Amphotericin B (AmB) is the main active ingredient in the most effective drug used to treat leishmaniasis, a disease which in the Western world mainly affects dogs, but in developing countries affects over 12 million people, with more than 70,000 deaths per year. The cost of treating humans with AmB surpasses $5,000 per patient, the treatment is extensive (2-hour sessions every day during 21 days), and the side effects are frequent and many times patients must be hospitalised.

Researchers from the University of Miami, Florida and the Universitat Autnoma de Barcelona have developed a method which allows to drastically reduce the drug dose, since it improves its efficacy 83%, multiplies by 10 the capacity of the drug to attack cell infected by the parasite which provokes the disease, and significantly reduces the toxicity of the parasite. The method has been successfully tested on mice models of leishmaniasis.

The complex compound acts through the action of the PDD nanoparticle, a substance measuring some 10 nanometres in diameter which is fit into the active principle, Amphotericin B, and guides it selectively to the cells harbouring the parasite. Scientists observed how, while the usual complete dose of the drug requires over 12 days to reduce the skin lesions caused by the disease, one dose of the complex compound with only 17% of the complete dose of the drug improves skin lesions in two or three days. Moreover, the complex compound acts as a therapeutic vaccine which activates the immune system against the reservoir cells hosting the parasite.

The PDD substance has been used in previous trials with people with the aim of improving the response of their immune system to other diseases. Now there is a need for clinical trials with humans in order to verify its safety as an adjuvant in the treatment of leishmaniasis. If its safety in humans is confirmed, it will also reduce the cost of the treatment drastically, and this is a key element in reducing mortality rates in developing countries.


'/>"/>

Contact: Jordi Alberola
jordi.alberola@uab.cat
34-935-811-532
Universitat Autonoma de Barcelona
Source:Eurekalert

Related medicine news :

1. Biosimulation Market (For Drug Discovery & Development) Worth $1.2 Billion by 2017 - New Report by MarketsandMarkets
2. Discovery could lead to anti-clotting drugs with less risk of bleeding
3. International group finds 11 new Alzheimers genes to target for drug discovery
4. Biosimulation Market (Drug Discovery & Development) Worth $1.2 Billion by 2017 - New Report by MarketsandMarkets
5. New Case Management Order in New Jersey DePuy ASR Recall Litigation Extends Discovery to June 2014, More than 650 Metal Hip Lawsuits Filed in Consolidated Proceeding
6. The Producers of the In View Series Announce Upcoming Airing on the Discovery Channel
7. Ethicon Transvaginal Mesh Lawsuits Move Forward, With Scheduling of Discovery Conferences in Federal Vaginal Mesh Litigation, Bernstein Liebhard LLP Reports
8. LDM Global eDiscovery Professional, Jennifer Holt, is Awarded CEDS Certification
9. Cancer/Tumor Profiling Market (Personalized Medicine, Biomarker Discovery, Prognosis, Research) Worth $35.03 Billion by 2018 – New Report by MarketsandMarkets
10. Propofol discovery may help lead to development of new anaesthetics
11. American Brain Tumor Association Seeks Inventive Ideas for Research Discovery Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Reflections Recovery ... now accredited by The Joint Commission for chemical dependency and behavioral health services. ... U.S. health care organizations that meet the commission’s rigorous standards. Accreditation by The ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... Clinical Plus Coating System for clients that rely on safety and cleanliness. This ... of microorganisms. , Silver has been used for centuries for its antimicrobial properties. ...
(Date:9/20/2017)... ... 2017 , ... Renal Support Network’s annual essay contest celebrates ... The theme “Describe a positive decision that you have made about your healthcare” ... one qualification— to have been diagnosed with chronic kidney disease. This year the ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... medical device compliance and commercialization, has just released a new white paper ... is more adamant than ever about medical device, pharmaceutical, and combination product ...
(Date:9/20/2017)... ... September 20, 2017 , ... Demand generation pioneer ... East-coast edition of MarTech: The Marketing Tech Conference October 2–4, at the Hynes ... 40 speakers — representing such thought-leading companies as JP Morgan Chase, GE ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
(Date:9/5/2017)... Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ... the development of oral drug delivery systems, announced today ... U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the ... At the meeting, the FDA gave clear ... would be a Biologics License Application (BLA).  Such a ...
(Date:8/31/2017)... -- PM360,s annual Innovations Issue, published in December, ... happening across the industry. Established six years ago, this ... a comprehensive look at the newest and most exciting ... companies, startups, divisions, products, services, and strategies from the ... in this industry wants to do better—in all facets ...
Breaking Medicine Technology: